Lymphoma Therapy

Idiotype-pulsed dendritic cell vaccination effective

Published in Blood Weekly, March 21st, 2002

by Michael Greer, senior medical writer - Dendritic cells (DCs) engineered to carry B-cell, lymphoma-specific antigens can help patients fight off malignancy, researchers in the United States say.

"Tumor-specific clonal immunoglobulin expressed by B-cell lymphomas (idiotype [Id]) can serve as a target for active immunotherapy," according to Dr. John M. Timmerman and colleagues at the Stanford University School of Medicine in Stanford, California.

Therapeutic vaccination with idiotype-pulsed DCs can slow or reverse tumor progression, Timmerman and coauthors found.

After achieving promising results in a preliminary study with 4...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2002-03-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry